CD19 and B-cell non-Hodgkin lymphoma: By quantitative flow cytometry of CD19 levels in large B cell lymphoma (LBCL) cells of patients after axicabtagene ciloleucel therapy, researchers revealed that 3,000 CD19 molecules per cell at baseline is the threshold level; lower CD19 levels on tumor cells stratifies patients with high risk of relapse (5).